IMRN
Immuron Ltd
$1.19
-4.03%
$8.0M
No data for this timeframe.
Vol
Market Cap$8.0M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$40.3K
Inst. Activity1 buys / 1 sells
SEC Reports5
Recent Activity
May 28, 2026
SEC
Immuron filed a 6-K containing its response to an ASX price query regarding a sharp price spike from A$0.032 to A$0.044
6-K — Impact 3/10
May 8, 2026
SEC
Immuron reported 3Q FY2026 global sales of A$1.5M (+16% YoY) and YTD sales of A$5.7M (+7% YoY), with Australian sales up
6-K — Impact 4/10
Apr 21, 2026
SEC
Immuron Limited reported unaudited Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by strong growth in Austra
PRESS-RELEASE — Impact 6/10
Inst.
MORGAN STANLEY — TRIM
30,574 shares ($23.7K)
Inst.
RHUMBLINE ADVISERS — ADD
7,367 shares ($5.7K)
Apr 17, 2026
earnings
Immuron Double Digit 3Q Sales Growth
<p><strong><em>Sales Highlights (unaudited):</em></strong></p>
Price Targets
Historical data — last covering-analyst action Sep 2024. No current recommendation available.
$3.95 (Sep 2024)
Current $1.19
Low $3.95
Median $3.95
High $3.95
1 analysts
$3.95
$3.95
Analyst Ratings
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 26, 2024 | Litchfield Hills | INITIATE | Buy |
| Oct 18, 2017 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-0.01 ▼ -16.7% | $-0.01 — $-0.01 | 48% YoY | 1 |
| Next FY | $-0.02 ▼ -25.8% | $-0.02 — $-0.02 | -27% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $23.7K | TRIM |
| CITADEL ADVISORS LLC | $10.7K | — |
| RHUMBLINE ADVISERS | $5.7K | ADD |
| BlackRock, Inc. | $174.00 | — |
4 institutional holders with $40.3K total value (51,970 shares) as of 2026-Q1. Top holders: MORGAN, CITADEL, RHUMBLINE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 30,574 | $23.7K | 58.8% | TRIM -46.7% |
| 2 | CITADEL ADVISORS LLC | 13,804 | $10.7K | 26.6% | — |
| 3 | RHUMBLINE ADVISERS | 7,367 | $5.7K | 14.2% | ADD +63.9% |
| 4 | BlackRock, Inc. | 225 | $174.00 | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 57,381 | 30,574 | -46.7% | $23.7K | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 4,496 | 7,367 | +63.9% | $5.7K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 18,253 | 57,381 | +214.4% | $43.8K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 700 | 18,253 | +2507.6% | $34.7K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 16,295 | 1,866 | -88.5% | $3.5K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 4,991 | 3,333 | -33.2% | $9.1K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
NEUTRAL
6-K
3/10
Immuron filed a 6-K containing its response to an ASX price query regarding a sharp price spike from
May 28, 2026
NEUTRAL
6-K
4/10
Immuron reported 3Q FY2026 global sales of A$1.5M (+16% YoY) and YTD sales of A$5.7M (+7% YoY), with
May 8, 2026
BULLISH
PRESS-RELEASE
6/10
Immuron Limited reported unaudited Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by str
Apr 21, 2026
BULLISH
6-K
6/10
Immuron Ltd reported unaudited Q3 sales growth of 16% year-over-year to AUD$1.5 million, driven by s
Apr 17, 2026
NEUTRAL
6-K
3/10
Immuron Ltd is offering a Small Holding Share Sale Facility allowing shareholders with holdings valu
Apr 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2024. No current recommendation available.
$3.95 mean target (Sep 2024)
$3.95 Low
$3.95 High
| Metric | Value |
|---|---|
| Current Price | $1.19 |
| Target Low | $3.95 |
| Target Mean | $3.95 |
| Target Median | $3.95 |
| Target High | $3.95 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | 47.6% | -16.7% | — | $0.0B | — | 1 |
| Next FY 2027-06-30 |
$-0.02 | $-0.02 | $-0.02 | -26.9% | -25.8% | — | $0.0B | 12.0% | 1 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 26, 2024 | Litchfield Hills | INITIATE | — | Buy |
| Oct 18, 2017 | HC Wainwright & Co. | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
Clinical Trial
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
Phase Phase 2 — COMPLETED
Apr 17, 2026
earnings
Immuron Double Digit 3Q Sales Growth
<p><strong><em>Sales Highlights (unaudited):</em></strong></p>
Mar 5, 2026
other
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
<p align="justify">MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and global